Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. Background and objective: Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.

  2. 2 gru 2021 · Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.

  3. 2 gru 2021 · Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients.

  4. 16 maj 2020 · The median age of study patients was 65 years (IQR 56–71); sex distribution was 89 (56%) men versus 69 (44%) women in the remdesivir group and 51 (65%) versus 27 (35%) in the placebo group (table 1). The most common comorbidity was hypertension, followed by diabetes and coronary heart disease.

  5. 2 maj 2022 · Summary. Background. The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued for futility but randomisation to remdesivir continued.

  6. 24 paź 2024 · Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world coho ... of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults . Management of vulnerable patients hospitalized for COVID-19 ...

  7. 30 lip 2020 · Recommendation 1 We suggest remdesivir rather than no remdesivir in patients with severe covid-19 Usual supportive care Remdesivir or 100 mg intravenously daily for 5-10 days No remdesivir Strong Weak Weak Strong Resource limited settings. Evidence profile. Individual considerations.

  1. Ludzie szukają również